Associated Papers
Potential Opportunities for Pharmacogenetic-Based Therapeutic Exploitation of Xanthine Dehydrogenase in Cardiovascular Disease.
Massimo G et al.
Antioxidants (basel, Switzerland), 2024
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
38802404 (PubMed )
Supplement: 41397_2024_338_MOESM2_ESM.xlsx › Sheet1
Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform.
Kim B et al.
Translational and Clinical Pharmacology, 2021
34621706 (PubMed )
Supplement: tcp-29-135-s001.xls › tcp-29-135-s001
An optimized prediction framework to assess the functional impact of pharmacogenetic variants.
Zhou Y et al.
The Pharmacogenomics Journal, 2019
30206299 (PubMed )
Supplement: 41397_2018_44_MOESM5_ESM.xlsx › Sheet1
Influences of XDH genotype by gene-gene interactions with SUCLA2 for thiopurine-induced leukopenia in Korean patients with Crohn's disease.
Park SK et al.
Scandinavian Journal of Gastroenterology, 2016
Xanthinuria type I with a novel mutation of xanthine dehydrogenase.
Tanaka K et al.
The American Journal of the Medical Sciences, 2015
Mutations associated with functional disorder of xanthine oxidoreductase and hereditary xanthinuria in humans.
Ichida K et al.
International Journal of Molecular Sciences, 2012
Novel mutations in xanthine dehydrogenase/oxidase cause severe hypouricemia: biochemical and molecular genetic analysis in two Czech families with xanthinuria type I.
Stiburkova B et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry, 2012
Kinetics of 6-thioxanthine metabolism by allelic variants of xanthine oxidase.
Kudo M et al.
Drug Metabolism and Pharmacokinetics, 2010
Functional characterization of human xanthine oxidase allelic variants.
Kudo M et al.
Pharmacogenetics and Genomics, 2008
Select a paper to view details